3 Results for "

area postrema

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "area postrema" in MCE Product Catalog:

Cat. No.: HY-P11320
CAS No.: 863919-85-1
Research Areas:  

Metabolic Disease

Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC50 = 0.04 nM), calcitonin receptor (IC50 = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC50 = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC50 = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes .
loading...
    loading...
Cat. No.: HY-P11321A
Synonyms: acyl-GIP hydrochloride
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

IUB0271 hydrochloride (acyl-GIP hydrochloride) is a glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist with blood-brain barrier permeability. IUB0271 hydrochloride activates the GIPR signaling pathway, inhibits food intake and weight gain, and induces cFos neuron activation in the area postrema. IUB0271 hydrochloride enhances lipid clearance and induces systemic fatty acid oxidation. IUB0271 hydrochloride improves dyslipidemia, reduces atherosclerotic plaque formation and decreases adipocyte volume. IUB0271 hydrochloride can be used in studies related to obesity, dyslipidemia and atherosclerosis .
loading...
    loading...
Cat. No.: HY-P11321
Synonyms: acyl-GIP
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

IUB0271 (acyl-GIP) is a glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist with blood-brain barrier permeability. IUB0271 activates the GIPR signaling pathway, inhibits food intake and weight gain, and induces cFos neuron activation in the area postrema. IUB0271 enhances lipid clearance and induces systemic fatty acid oxidation. IUB0271 improves dyslipidemia, reduces atherosclerotic plaque formation and decreases adipocyte volume. IUB0271 can be used in studies related to obesity, dyslipidemia and atherosclerosis .
loading...
    loading...